Cardiol Therapeutics Inc (CRDL) FinancialsCRDLFinancialCardiol Therapeutics Inc

Evaluating the bottom line, Cardiol Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -190.18%, provide a clear picture of how effectively CRDL converts its operational activities into shareholder value.

In the context of the broader market, CRDL competes directly with industry leaders such as IFRX and FATE. With a market capitalization of $250.00M, it holds a significant position in the sector. When comparing efficiency, CRDL's gross margin of N/A stands against IFRX's N/A and FATE's 100.00%. Such benchmarking helps identify whether Cardiol Therapeutics Inc is trading at a premium or discount relative to its financial performance.

The company has a current ratio of 5.55, indicating strong liquidity, and has raised $13.5 million through a private placement, enhancing its financial position for growth.